The estimated Net Worth of Ronald C Jr Renaud is at least $40.5 Million dollars as of 7 April 2021. Mr. Renaud owns over 9,026 units of Telesis Bio Inc stock worth over $855,646 and over the last 10 years he sold TBIO stock worth over $36,254,014. In addition, he makes $3,386,150 as President, Chief Executive Officer, and Director at Telesis Bio Inc.
Sign up
Mr. Renaud TBIO stock SEC Form 4 insiders trading
Ronald has made over 5 trades of the Telesis Bio Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he sold 954,053 units of TBIO stock worth $36,254,014 on 14 September 2021.
The largest trade he's ever made was selling 954,053 units of Telesis Bio Inc stock on 14 September 2021 worth over $36,254,014. On average, Ronald trades about 38,027 units every 92 days since 2014. As of 7 April 2021 he still owns at least 503,321 units of Telesis Bio Inc stock.
You can see the complete history of Mr. Renaud stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Ronald Renaud biography
Ronald C. Renaud Jr. serves as President, Chief Executive Officer, Director of the Company. He has served as our president and chief executive officer and as a member of our board of directors since November 2014. Formerly, Mr. Renaud served as president and chief executive officer of Idenix Pharmaceuticals, a biopharmaceutical company, from 2010 until Idenix was acquired by Merck & Co., Inc., a pharmaceutical company, in August 2014. He was previously chief financial officer and chief business officer of Idenix from 2007 until his appointment as chief executive officer. Prior to joining Idenix, he served as senior vice president and chief financial officer of Keryx Biopharmaceuticals. Mr. Renaud is a member of the board of directors of Chimerix, Inc. and served as a member of the board of directors of Akebia Therapeutics, Inc. from 2014 until 2018. Mr. Renaud received a B.A. from St. Anselm College and an M.B.A. from the Marshall School of Business at the University of Southern California.
What is the salary of Ronald Renaud?
As the President, Chief Executive Officer, and Director of Telesis Bio Inc, the total compensation of Ronald Renaud at Telesis Bio Inc is $3,386,150. There are no executives at Telesis Bio Inc getting paid more.
How old is Ronald Renaud?
Ronald Renaud is 51, he's been the President, Chief Executive Officer, and Director of Telesis Bio Inc since 2014. There are 8 older and 5 younger executives at Telesis Bio Inc. The oldest executive at Telesis Bio Inc is Jean-Francois Formela, 63, who is the Independent Director.
What's Ronald Renaud's mailing address?
Ronald's mailing address filed with the SEC is C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BOULEVARD, SUITE 900, SOUTHN SAN FRANCISCO, CA, 94080.
Insiders trading at Telesis Bio Inc
Over the last 6 years, insiders at Telesis Bio Inc have traded over $269,224,467 worth of Telesis Bio Inc stock and bought 73,047,057 units worth $2,753,701,666 . The most active insiders traders include Sanofi, Plc Gsk, and Human Genetic Therapies, In.... On average, Telesis Bio Inc executives and independent directors trade stock every 88 days with the average trade being worth of $7,100,681. The most recent stock trade was executed by Todd Robert Nelson on 4 May 2023, trading 2,575 units of TBIO stock currently worth $7,287.
What does Telesis Bio Inc do?
sgi-dna, a wholly owned subsidiary of synthetic genomics inc., provides genomic solutions to advance scientific discovery. sgi-dna’s ever expanding suite of products, services, reagents, bioinformatics tools and instrumentation enables scientists to discover, design and build novel solutions for basic research, as well as for biomedical and industrial applications. sgi-dna’s genomic services include whole genome sequencing, dna synthesis, library design, bioinformatics, cell engineering, and plasmid dna cloning and purification. sgi-dna’s reagents include a complete suite of gibson assembly® and site directed mutagenesis kits as well as optimized cell lines such as vmax™ a novel, fast growing host system for molecular biology. to further enable synthetic biology workflows, sgi-dna offers the bioxp™ 3200 system. this fully automated genomics workstation allows the creation of double stranded dna fragments, automated cloning, as well as next generation sequencing dna library preparation.
What does Telesis Bio Inc's logo look like?
Complete history of Mr. Renaud stock trades at Akebia Therapeutics, Atara Biotherapeutics Inc, Chimerix Inc, PTC Therapeutics Inc, and Telesis Bio Inc
Telesis Bio Inc executives and stock owners
Telesis Bio Inc executives and other stock owners filed with the SEC include:
-
Ronald Renaud,
President, Chief Executive Officer, Director -
Richard Wooster,
Chief Scientific Officer -
John Schroer,
Chief Financial Officer, Treasurer -
Brian Fenton,
Chief Business Officer -
Robert Plenge,
Independent Director -
Robert Meyer,
Independent Director -
George Demetri,
Independent Director -
Daniel Lynch,
Independent Chairman of the Board -
Daniella Beckman,
Independent Director -
Owen Hughes,
Independent Director -
Jean-Francois Formela,
Independent Director -
Ann Barbier,
Chief Medical Officer -
Frank DeRosa,
Chief Technology Officer -
Paula Cloghessy,
Chief Human Resource Officer -
Paul Burgess,
Chief Operating Officer, Chief Legal Officer -
Michael Heartlein,
Founder, Executive Vice President -
Paul M Meister,
Director -
Everett Rand Sutherland,
President -
Brian M. Jr. Gallagher,
Director -
Ventures Fund Llc Mrl,
10% owner -
Venture Fund Viii, L.P.Atla...,
-
Plc Gsk,
10% owner -
Human Genetic Therapies, In...,
-
Fund Iv, L.P.Omega Fund Iv ...,
-
James B Weissman,
-
Michael R. Hodges,
-
Todd Krueger,
-
Steven J Golub,
-
Sarah E. Hlavinka,
-
Daniel Glenn Gibson,
Chief Technology Officer -
Human Genetic Therapies, In...,
-
Group Llc/Ma Baupost Group ...,
-
Brendan Smith,
Chief Financial Officer -
Sanofi,
10% owner -
Ventures Gp, Llc Northpond ...,
-
Fund Iv, Llc Broad Oak,
10% owner -
William Snider,
Director -
William J Kullback,
Chief Financial Officer -
Rob Cutler,
Chief Legal Officer -
Todd Robert Nelson,
Chief Executive Officer -
Eric Eugene Esser,
President & CEO -
Frank Witney,
-
Christine A Tsingos,
-
Annette Tumolo,
-
Gregory J. Herrema,
-
Jami K Nachtsheim,